



December 20, 2016

Novartis Pharma AG

CH-4002, Basel, Switzerland

Reference: EudraCT 2011-001824-39/ Novartis Protocol ID CMID001A2201

*A randomized, double-blind, double-dummy, placebo-controlled, 3-period crossover study to evaluate the pharmacodynamics, pharmacokinetics, safety and tolerability of orally inhaled indacaterol administered via the EPIC test fixture and the Concept1 device in adult patients with persistent asthma.*

Trial CMID001A2201 was cancelled with no patient enrollment and as such, no results will be reported.